Rosa & Co. LLC is currentlly seeking a leader with a strong scientific background to support client business development activities. Reporting to the Senior Vice President of Scientific Alliances, the ideal candidate will partner with Clients Services on existing accounts and provide research and support for new account opportunities. (Announcement, pdf)
Rosa & Co. LLC, is pleased to announce the initiation of a multi-year Research Agreement with Sanofi Global R&D to provide Rosa’s market-leading PhysioPD services to worldwide Sanofi affiliates. The collaboration provides Sanofi a competitive research and development advantage and greater access to the extensive depth and breadth of Rosa’s expertise. Rosa’s agreement with Sanofi further extends Rosa’s presence as the global market leader in the Quantitative Systems Pharmacology field. (Press release)
Dr. Ananth Kadambi delivered the Keynote Address at the QSP Congress on April 28, 2015 in Basel, Switzerland. He discussed the philosophical and practical roles of QSP in the scientific process, common R&D applications, and key aspects of QSP market adoption. Additionally, on April 29, 2015, Dr. Mike Reed presented a significant case study that covered creating and performing research with PhysioPD™ Research Platforms. Rosa also participated in two panel discussions during the conference on current and future applications of QSP. (Press release)
Bristol-Myers Squibb and Rosa to present a poster describing a Virtual Systems Pharmacology (ViSP) web-based environment at the ASCPT 2015 Annual Meeting in New Orleans, LA. The poster, entitled “Virtual Systems Pharmacology (ViSP) flexible web-based environment for running large multi-scale models” will be presented by Tarek Leil, Ph.D. during the Quantitative Systems Pharmacology Pre-Conference Poster Session on Tuesday, March 3, 2015, 12:45 PM - 1:45 PM at the Hyatt Regency, Elite Foyer, and during the Late-Breaking and Encore Poster Session I on Thursday, March 5th, 2015 from 4:30 – 6:30 PM at the Hyatt Regency, Elite Hall. (Abstract)(Press release)
Dr. Ron Beaver will present a keynote session at the QSP Congress Boston 2015 Meeting at Le Meridien Hotel, Cambridge, MA on Wednesday, January 28th, 2015 at 10:20 – 10:50 a.m. His talk is entitled “Systems Pharmacology: Science and Non-Science? And so What?”
Dr Christina Friedrich will lead the pre-conference workshop at the QSP Congress Boston 2015 Meeting at Le Meridien Hotel, Cambridge, MA on Tuesday, January 27th, 2015 at 9:00 – 12:00 p.m. Her workshop is entitled “Using Mechanistic Physiological Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach.”
Dr. Ananth Kadambi will be speaking at the 19th North American ISSX Meeting/29th JSSX Meeting at the Hilton, San Francisco, on Wednesday, October 22, 2014 at 9:00 - 11:30 a.m. His talk is entitled “Application of Quantitative System Pharmacology Modeling to Translational Research”.
Dr Christina Friedrich will be speaking at the American Conference on Pharmacometrics (ACoP) in Las Vegas NV, on Monday, October 13th at 3-5 pm. Her talk is entitled “Quantitative Systems Pharmacology (QSP) informs in vitro to in vivo translation for PCSK9 antibody”.
Rosa's Dr. Gordi will be speaking to the Bio2Device Group in Sunnyvale, CA, on Aug. 26, 8:30 A.M. In his talk, entitled "Drug Development in silico: Models and Their Utility", Dr. Gordi will discuss the various types of study models and their application to the drug development process. (Abstract)
MedImmune and Rosa presented a poster, entitled "Quantitative Systems Pharmacology Modeling to Evaluate Clinical Response of an anti-TNFa/anti-Ang2 Bispecific Antibody in Rheumatoid Arthritis" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 20, 2014. The poster describes a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of rheumatoid arthritis, designed to address the target-mediated drug disposition kinetics of a bispecific antibody directed against TNFa and angiotensin 2. (Abstract)
Amgen and Rosa presented a poster, entitled "Pharmacology Model to Characterize the Effect of Blinatumomab in Patients With Adult B-Precursor Acute Lymphoblastic Leukemia" at the American Society of Clinical Phamacology and Therapeutics Conference in Atlanta, GA on March 18 (Biologics pre-conference) and 21, 2014. The poster describes key questions addressed with a quantitative systems pharmacology model (PhysioPD™ Model) that represents the pathophysiology of B-Precursor Acute Lymphoblastic Leukemia and the effect of blinatumomab, a T-cell activator that leads to B-cell death.
Rosa is pleased to announce the appointment of Ananth Kadambi, PhD, as Senior Vice President, PhysioPD, to manage their rapidly-expanding business in Japan and Asia. Dr. Kadami comes to Rosa from Evidera, where he served as as the Director of Modeling and Simulation. Previous to that, Dr. Kadambi rose from Team Leader to Vice President at Entelos Holdings, Inc. (Press release)
Rosa is pleased to announce the acquisition of the consulting service business of Entelos Holdings, Inc., which conducts mechanistic, physiologic, in silico modeling projects for customers in pharmaceutical research and development. The acquisition, which closed January 7, 2014, further extends Rosa’s presence in quantitative systems pharmacology and modeling and simulation research services and adds to Rosa's already significant expertise in cardiovascular, immunology, and metabolism biology, and human nutrition. (Press release)
Rosa is pleased to announce it has established an alliance with the KressWorks Foundation to develop a Ewing’s Sarcoma PhysioPD Research Platform, a quantitative model of the physiologic and pharmacologic mechanisms involved in Ewing’s Sarcoma. (Press release)
Rosa is pleased to announce that Katherine Kudrycki, Ph.D. has joined Rosa as Principal Scientist. In addition, Rosa has expanded its engineering team. (Press release)
Rosa will be presenting a talk entitled “Application of a physiologically-based model incorporating drug-specific PK modules to support optimization of GLP-1 receptor agonist combination therapies for type 2 diabetes” at the AAPS meeting on November 10-14, 2013 in San Antonio, Texas. (Abstract, Press release)
As the Expertise Partner, Rosa will be presenting the plenary session presentation entitled “Accomplishments and Challenges in Systems Pharmacology” at the Integrating Pharmacometrics Summit in Munich, Germany, Oct 21-23 2013. Dr. Ron Beaver will discuss the volume of experience and the wide-use of the systems pharmacology approach; what decisions in drug development can be supported; how we think about “value” and how we judge “quality”; dealing with scepticism and setting projects up for success; and how we apply this approach systematically to our pipeline. (Press Release)
The American Association of Pharmaceutical Scientists Bay Area Discussion Group will meet on Sept 12, 2013. Rosa's Dr. Toufigh Gordi will present a talk entitled "Models and Their Utility in the Drug Development Process" (Flyer)
Rosa offers a free download of its Model Qualification Method (“MQM”), published in the White Paper, “Facilitating Drug Discovery and Development with Mechanistic Physiological Models that are ‘Fit for Purpose’”, to facilitate the broader adoption and use of mechanistic, physiologic models in pharmaceutical research and development. Rosa is also offering MQM-focused educational activities in 2012 in the EU and US. On March 2, 2012, there will be a seminar sponsored by an industry group in the San Francisco Bay Area (www.bapkpd.org); workshops will be offered on March 27 – 29, 2012 at the 3rd Annual World PK/PD Summit, in Boston (pkpd-summit.com) and on April 1 – 4, 2012 at the 5th Annual EFMC Short Course on Medicinal Chemistry, in Leiden, The Netherlands. (Press Release)